Market capitalization | $931.68m |
Enterprise Value | $393.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 182.28 |
P/S ratio (TTM) P/S ratio | 431.33 |
P/B ratio (TTM) P/B ratio | 1.85 |
Revenue (TTM) Revenue | $2.16m |
EBIT (operating result TTM) EBIT | $-134.45m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:
5 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.16 2.16 |
-
|
|
Gross Profit | -1.22 -1.22 |
408%
408%
|
|
EBITDA | -134 -134 |
30%
30%
|
EBIT (Operating Income) EBIT | -134 -134 |
30%
30%
|
Net Profit | -532 -532 |
542%
542%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Head office | United States |
CEO | David Hung |
Employees | 51 |
Founded | 2018 |
Website | www.nuvationbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.